Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets
Interesting developments at the nanoparticle–protein interface: implications for next generation drug delivery
Researchers from the Texas A&M Health Science Center College of Medicine (Round Rock, TX, USA) are developing an inhalable form of ibuprofen, which could be used to treat cystic fibrosis patients without the negative side effects associated with high doses of ibuprofen.
An international team of researchers has published proof of principle for the first safe way to provide targeted drug delivery to the placenta during pregnancy, which may lead to future treatments for complications experienced in pregnancy.
Researchers at the Massachusetts Institute of Technology (Cambridge, MA, USA) and Brigham and Women’s Hospital (Boston, MA, USA) have developed novel nanoparticles capable of delivering anti-obesity therapeutics directly to fat tissue.